Cambridge: Moderna, Inc. has announced Health Canada has approved mRESVIA (Respiratory Syncytial Virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease ...

The approval marks the introduction of the first mRNA RSV vaccine in Canada. Credit: MargJohnsonVA via Shutterstock. Moderna has received Health Canada’s approval for its respiratory syncytial virus ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Health Canada has approved the vaccine, mRESVIA, for the prevention of lower respiratory tract disease in older adults, the company said.

An initial 899,000 vaccine doses have been allocated for nine countries across Africa that have been hit hard by the current mpox surge, the WHO and other health organizations say.

An initial 899,000 vaccine doses have been allocated to Nigeria and 8 other countries across Africa that have been hit ...

The global health agency said on Wednesday the newly allocated vaccines will go to the Central African Republic, Ivory Coast, the Democratic Republic of Congo, Kenya, Liberia, Nigeria, Rwanda, South A ...

Canada’s panel of vaccine advisers has strongly recommended the new vaccines targeting the KP.2 strain, part of the Omicron lineage, for the previously vaccinated or unvaccinated at increased risk of ...

GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...